Extramedullary (EM) involvement occurs infrequently in acute promyelocytic leukemia (APL) and usually involves skin and CNS. We describe seven patients (four observed at a single institution) who relapsed in various sites of the auditory apparatus, including the external canal and middle ear (temporal bone). Front-line treatment included ATRA and chemotherapy (six patients) or chemotherapy alone (one patient). Three patients had concomitant hematologic relapse, two had molecular relapse and two were in hematologic and molecular remission when ear localization was documented. Local symptoms that stimulated further diagnostic studies included ear bleeding/discharge in the first patient, but were mild in the others (hypoacusia, five patients; earache, two patients). Ear involvement by leukemia was documented by histological and/or molecular studies after local surgery in five cases, and by CT scan or NMR in the remaining patients. We suggest that the ear might represent a specific sanctuary for disease involvement in APL.
Introduction
Acute promyelocytic leukemia (APL) is a peculiar subtype of acute myeloblastic leukemia (AML) characterized by consistent clinical, morphologic and genetic features including a severe hemorrhagic syndrome, a unique t(15;17) translocation and response to the differentiating agent all-trans retinoic acid (ATRA). [1] [2] [3] The introduction of this agent in combination with anthracycline-containing chemotherapy has considerably improved the outcome of APL patients, as reported by several multicenter studies conducted worldwide during the past decade. [4] [5] [6] [7] [8] [9] [10] [11] [12] Historically, disease relapse in extramedullary (EM) sites has been described less frequently in APL than in other AML subsets. 13, 14 However, over the past few years an increasing number of EM localizations in APL patients at relapse has been reported, with most commonly involved sites being the CNS, cutis and lymph nodes. [14] [15] [16] [17] [18] This has been attributed by some authors to a direct effect of ATRA on APL cells, such as modulation of adhesion molecules which may enhance the infiltration capability of leukemia blasts. 16 Alternatively, others have hypothesized that the apparently increased EM involvement in APL simply reflects the fact that more cases are being described as a consequence of an increased risk exposure, which in turn is due to improved prognosis and prolonged survival. 18 Amongst EM sites involved in leukemias, infiltration of the ear is exceedingly infrequent and only anecdotal cases have [19] [20] [21] [22] [23] [24] Anatomical and or biological reasons underlying this particular disease localization are unknown. In the present study, we report seven cases of APL relapse in the auditory apparatus, four of which were observed at a single institution. Documentation of disease localization in such an unusual site was provided by local biopsy, molecular biology and/or immunophenotypic staining, demonstrating the specific APL-associated genetic lesion.
Patients and methods
Seven patients with APL who relapsed in the auditory apparatus are reported. Of these, four were diagnosed at the Department of Human Biotechnology and Hematology of the University La Sapienza of Roma, while three were reported from dedicated centers to the GIMEMA (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto) Data Center. The main clinical and biologic characteristics of the seven patients at presentation are reported in Table 1 . Three of these cases are included in a series of EM relapses recently reported. 18 No specific description of patient characteristics are made in that article, where only CNS relapses are reported in details. 18 In all cases, APL diagnosis was confirmed at the genetic level by presence of t(15;17) and/or PML/RAR␣ fusion as described. 5 Immunophenotypic characterization was also performed at diagnosis, using a wide panel of monoclonal antibodies including CD13, CD33, HLA-DR, CD34, CD2, CD9, CD56. With regard to initial therapy, six patients were enrolled in the AIDA 0493 study and were treated with ATRA and idarubicin followed by three polychemotherapy consolidation cycles as reported. 5 One patient, diagnosed in July 1990, received chemotherapy alone according to the 0389 GIMEMA study. 18 With respect to the diagnosis of ear involvement, this was based on CT scan and/or NMR images in two patients and in morphologic, immunofluorescence and molecular studies in material collected after local surgery in five patients. Of these, four underwent mastoidectomy of the temporal bone. Morphologic, immunofluorescence and molecular analyses included RT-PCR and staining of bioptic cells with the PG-M3 monoclonal antibody to determine the pattern of PML distribution. The methods for RT-PCR of PML/RAR␣ and indirect immunofluorescence for PML staining pattern are reported elsewhere.
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Results
The main clinical and biologic features of the seven patients at time of initial diagnosis are shown in Table 1 . Two of the seven patients had hyperleukocytosis. Long and short PML/RAR␣ isoforms were detected in four and two cases, AIDA, all-trans retinoic acid and idarubicin; CHT, chemotherapy; IDA, idarubicin; Ara-C, cytarabine; ND, not determined.
respectively. None of the six patients treated with the AIDA regimen developed ATRA syndrome during front-line therapy. In addition, no peculiarities were observed as regards the immunophenotypic profile of leukemic cells at diagnosis. CD56 expression was negative in four patients whose blasts were evaluated at presentation for the expression of this molecule.
The diagnosis of ear relapse was made in the first patient (No. 1 in Tables 1 and 2 ) following histologic examination of a small myeloblastoma of the external canal, noted after left ear bloody discharge. In the remaining cases, leukemic infiltration in the ear was suspected based on NMR or CT scan of the ear and temporal bone which were performed due to local symptoms such as hypoacusia, and/or earache ( Table 2) . NMR revealed in cases 1, 2, 3, 4, 6, 7 the presence of a signal hyperintensity corresponding to the mastoid bone in T2-pulsed sequences.
Three patients (Nos 2, 3, 4) underwent mastoidectomy at the time of suspected ear relapse. Infiltration of the auditory a1 and b1) carried out in bioptic material obtained from the mastoid bone in patients 2 and 3.
Ear involvement was diagnosed at extremely variable time intervals, ie at 5-69 months from the achievement of first hematologic remission in cases 1-6. In patient 7, ear localization was observed at 6 months after second remission (Table  1) . When ear localization was documented, two patients (Nos 4 and 5) had concomitant hematologic relapse, three patients (Nos 1, 2, 7) had molecular relapse (ie PCR-positive test for PML/RAR␣ in the marrow) and 2 (Nos 3 and 6) were in hematologic and molecular remission ( Table 2) . Two patients (Nos 6 and 7) had concomitant CNS involvement documented by lumbar puncture followed by light microscopy and molecular detection of leukemic cells.
Discussion
To the best of our knowledge, a total of seven cases of APL relapse in the ear have been reported to date. [20] [21] [22] [23] [24] All these ear relapses were described as case reports and were diagnosed in Japan (five cases) [20] [21] [22] [23] or in Hong Kong (two cases). 24 Three of the five reports were published in Japanese [21] [22] [23] and two in the English literature. 20, 24 Involved anatomic sites in the above studies included the external auditory canal, middle ear and mastoid air cells. Interestingly, in two patients described in separate reports leukemia infiltration of the ear was bilateral with both auditory canals being occluded by tumor masses. 23, 24 Given the difficulty in accessing Japanese reports, we are unsure whether laboratory molecular tests were performed in any of the previously reported cases.
As occurred in our experience, it is conceivable that the first observed case led to more accurate investigations at this specific anatomic site. In this respect, we noted that four of seven patients were diagnosed at a single institution, where Leukemia ear relapses accounted for 40% of all extramedullary APL relapses (four out of 10 since the start of the AIDA study in 1993, data not shown). This indicates an unexpectedly high frequency of this localization in APL. On the other hand, it suggests that clinicians already aware of this phenomenon are probably more prone to investigate symptoms related to the auditory apparatus in these patients. In this respect, it may be observed that, while the first patient in our series had ear bleeding and an external myeloblastoma, the other patients only complained of more vague symptoms such as hypoacusia and/or earache ( Table 2 ). Hypoacusia and other mild hearing disturbances might be frequent in leukemia patients receiving, for example, prolonged antibiotic treatment with aminoglycosides and it is quite unlikely that these symptoms are related to leukemia infliltration. Due also to the frequent concomitance of relapse in other sites which is treated with systemic therapy, it is possible that ear disease localization may remain undetected, particularly in those patients complaining of only mild symptoms. Indeed, six of seven patients in the present series had simultaneous involvement of other sites (bone marrow and/or CNS) at the time of ear relapse. However, bone marrow disease involvement was minimal in three of our cases, being only detectable at the PCR level (molecular relapse).
As to the possible pathogenetic mechanisms which have been hypothesized to explain this unexpected finding, some authors suggested a role for ATRA during front-line therapy as a predisposing factor. 16 ATRA has been shown to influence the expression of adhesion molecules on leukemic cells, [26] [27] [28] and this in turn might be associated with the pathophysiology of extramedullary involvement in APL patients receiving this agent. However, both in our series and in Japanese reports, [20] [21] [22] [23] APL relapse in the ear was also observed before the advent of ATRA in patients treated with chemotherapy alone. Although an extensive characterization of adhesion molecules at diagnosis was not available in our series, no correlation was found in this study with the cellular/neural adhesion molecule CD56 that we and others have recently reported as being associated with adverse outcome in APL. 29, 30 In fact, all four patients analyzed tested negative for CD56 expression. Similarly, staining of leukemic cells was negative for the CD56 antigen in the case recently reported by Au et al. 24 Finally, it should be noted that the mastoid is a bony structure that may contain bone marrow. Therefore, disease localization in the mastoid might not be strictly interpreted as an extramedullary sanctuary. However, it is conceivable that, for unknown reasons, APL cells spread from the mastoid cavity into the ear and originate a disease sanctuary. It also remains to be established why this phenomenon is apparently associated with only this leukemic subset. Specific investigations are needed to explain the pathogenesis of this rare infiltrate which may represent a further peculiarity of APL.
